Organogenesis Holdings Inc (ORGO) - Total Liabilities
Based on the latest financial reports, Organogenesis Holdings Inc (ORGO) has total liabilities worth $123.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Organogenesis Holdings Inc (ORGO) cash conversion ratio to assess how effectively this company generates cash.
Organogenesis Holdings Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how Organogenesis Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Check Organogenesis Holdings Inc (ORGO) asset resilience to evaluate the company's liquid asset resilience ratio.
Organogenesis Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Organogenesis Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sinomach General Machinery Science Technology Co Ltd
SHG:600444
|
China | CN¥760.72 Million |
|
Shandong Huifa Foodstuff Co
SHG:603536
|
China | CN¥834.54 Million |
|
A-LIVING SM.CI.SV. H YC 1
F:1V0
|
Germany | €9.07 Billion |
|
UD Electronic
TWO:3689
|
Taiwan | NT$1.93 Billion |
|
TSS, Inc. Common Stock
NASDAQ:TSSI
|
USA | $74.90 Million |
|
Shenzhen Friendcom Technology Development Co Ltd
SHE:300514
|
China | CN¥404.45 Million |
|
Eurocharm Holdings Co Ltd
TW:5288
|
Taiwan | NT$1.32 Billion |
|
Meter Instruments Co. Ltd
SHE:301006
|
China | CN¥189.00 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Organogenesis Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ORGO market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Organogenesis Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Organogenesis Holdings Inc (2001–2024)
The table below shows the annual total liabilities of Organogenesis Holdings Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $112.57 Million | -37.93% |
| 2023-12-31 | $181.36 Million | -1.27% |
| 2022-12-31 | $183.69 Million | -9.03% |
| 2021-12-31 | $201.92 Million | +36.06% |
| 2020-12-31 | $148.41 Million | -10.11% |
| 2019-12-31 | $165.10 Million | +41.55% |
| 2018-12-31 | $116.64 Million | +689.22% |
| 2017-12-31 | $14.78 Million | +30.46% |
| 2016-12-31 | $11.33 Million | +2620.33% |
| 2015-12-31 | $416.43K | -91.14% |
| 2001-12-31 | $4.70 Million | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more